P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.

Venclexta (venetoclax) - Roche, AbbVie

Xospata (gilteritinib) - Astellas

inobrodib (CCS1477) - CellCentric

http://www.ncbi.nlm.nih.gov/pubmed/42139346

Amanda M Versace; Chetan Jeurkar; Jennifer S Romer-Seibert; Kris Frese; Melanie L Goetz; Nigel Brooks; Robert L Bowman; Sara E Meyer; Scott Kogan

May 18, 2026